Enamine and H. Lundbeck A/S (Lundbeck) announced the expansion of their research collaboration. Enamine will support Lundbeck’s in-house discovery chemistry competencies with three principal assets enabling Lundbeck to optimally identify and develop hit series in its multiple research programs. A large diverse library of 100 000 new screening compounds was done for hit finding activities on numerous therapeutic targets. Enamine’s make-on-demand REAL compounds are for efficient access to billions of novel chemical compounds. Enamine FTE increased dedicated team of chemists to effectively support Lundbeck on all hit related follow-up activities backed by immediate access to over 170 000 building blocks in Enamine’s inventory.
Scientists at the UCSF, together with colleagues at the UNC, created the largest “docking-friendly” database of molecules, based on the Readily Accessible (REAL) compounds from Enamine. Practical validation of the new database was recently published in Nature magazine, demonstrating that it is capable of identifying extremely powerful and synthetically available new hits.
EU-funded project PELICO, under Enamine’s coordination, reports promising results in synthesis of peptides, their pharmacokinetic and toxicity studies, and coupling with photo-controlled building blocks to yield new photo-controlled peptidomimetics.
Enamine is a global supplier driven by people with passion to Chemistry. Over twenty years we have been committed to serving our customers in diversified markets ranging from screening libraries discovery to building blocks for medicinal chemistry and biological screening services. In order to meet their high expectations, we have gathered a team of motivated chemists and biologists and equipped our numerous labs and production facilities with state of the art equipment and quality control systems. We are constantly developing to address the challenges of dynamically evolving drug discovery industry.
With the thought of our customers, we have adopted high level of business process automation and resource management to timely deliver products of highest quality and competitive prices. Over the years we have created smart IT systems simplifying life for our employees and making business more efficient.
In order to assemble a focused small-molecule subset to tackle this interaction, we turned our attention to the published structural data. We built our pharmacophore model taking into consideration the reported helix-helix interaction between the two biological molecules. Specifically, we investigated the key H-bonds between H358, R359 (Bcl9) and D162, D164 (β-catenin) (Figure 1). Following docking and prioritization studies of our medchem compound selection, we picked molecules that i) secured hydrogen bonding with D162/D164 and ii) exhibited a significant β-stacking/hydrophobic interaction area with β-catenin to result in 1 779-compound library.
Fig. 1.(a)β-catenin/BCL9 helix-helix interaction interface featuring key hydrogen bonds; (b) binding of β-catenin and a representative ligand from the focused subset.
[submenu-wnt-lib][/submenu-wnt-lib]
FOLLOW US
E-newsletter
Thank you! Please check your email and confirm the newsletter subscription.
Your subscription was updated
Request product information
Please leave your request for any product you wish. We will be happy to search it for you in our databases or offer its custom synthesis
Video:
